{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:49:15Z","timestamp":1784944155350,"version":"3.55.0"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The PERPRISE study (Study 509; NCT04202159) was a prospective, observational, non\u2010interventional study in a real\u2010world setting in Germany. This study was conducted to evaluate the effectiveness of perampanel as the only adjunctive treatment for 12\u2009months in patients aged \u226518\u2009years with focal to bilateral tonic\u2013clonic seizures (FBTCS) or generalized tonic\u2013clonic seizures (GTCS) in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with FBTCS or GTCS received perampanel as an adjunctive therapy to anti\u2010seizure medication (ASM) monotherapy (add\u2010on therapy) or as a substitute for one ASM in dual therapy (substitution therapy) per the approved indication. The primary endpoint was the 12\u2010month retention rate of perampanel; the secondary endpoints were the 6\u2010month retention rate, seizure freedom for FBTCS or GTCS at 12\u2009months, and safety and tolerability. Exploratory endpoints included efficacy assessments by seizure type at 6 and 12\u2009months and patient\u2010reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 185 patients enrolled in the study, 183 patients were included in the full analysis set (add\u2010on, 86 patients; substitution, 96 patients; missing, 1 patient). The 12\u2010month retention rate was 66.7% (add\u2010on, 67.4%; substitution, 66.7%); the 6\u2010month retention rate was 80.3% (add\u2010on, 82.6%; substitution, 78.1%). At 12\u2009months, the seizure\u2010freedom rate for FBTCS or GTCS was 42.3% (add\u2010on, 51.7%; substitution, 35.1%). Treatment\u2010emergent adverse events (TEAEs) occurred in 44.0% of patients; 6.0% of patients reported serious TEAEs, and 16.5% of patients withdrew from the study due to TEAEs. Treatment with perampanel did not adversely affect cognitive function in patients with FBTCS or GTCS, and improvements in quality of life were reported by patients at both 6 and 12\u2009months following perampanel initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Findings from the PERPRISE study suggest that perampanel as an only adjunctive therapy is associated with favorable retention rates and good tolerability in patients with FBTCS or GTCS in a real\u2010world clinical setting in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>Patients with epilepsy often take multiple treatments to control their seizures. It is important to look at how well they work in everyday life. This study looked at adult patients in Germany taking perampanel added to one other epilepsy treatment. After 1\u2009year, 58 of 137 patients suffering from the most severe type of seizure were free of them. Side effects occurred in 80 patients (most commonly dizziness, fatigue, and nausea) and caused 30 of them to withdraw from treatment. Perampanel was effective and did not seem to negatively affect patients' thinking ability or quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epi4.70117","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:38:37Z","timestamp":1755794317000},"page":"1489-1504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of perampanel as the only adjunctive anti\u2010seizure medication in adults: Final results from the observational\n                    <scp>PERPRISE<\/scp>\n                    study in Germany"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-5862","authenticated-orcid":false,"given":"Bernhard J.","family":"Steinhoff","sequence":"first","affiliation":[{"name":"Kork Epilepsy Center  Kehl\u2010Kork Germany"},{"name":"Clinic for Neurology and Neurophysiology, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-9144","authenticated-orcid":false,"given":"Tobias","family":"Goldmann","sequence":"additional","affiliation":[{"name":"Eisai GmbH  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Kockelmann","sequence":"additional","affiliation":[{"name":"Eisai GmbH  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-4038","authenticated-orcid":false,"given":"Yaroslav","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Saarland  Homburg Germany"},{"name":"Department of Neurology Philipps\u2010University Marburg  Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"e_1_2_14_2_1","unstructured":"World Health Organization (WHO).Epilepsy.2025. Available from:https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/epilepsy. Accessed April 16 2025."},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010267"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.10.011"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.11.006"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.09.027"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_710_15"},{"key":"e_1_2_14_8_1","unstructured":"Food and Drug Administration (FDA).FYCOMPA\u00ae prescribing information.2025. Available from:https:\/\/www.fycompa.com\/media\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf. Accessed April 16 2025."},{"key":"e_1_2_14_9_1","unstructured":"European Medicines Agency (EMA).FYCOMPA\u00ae annex I: summary of product characteristics.2025. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/fycompa\u2010epar\u2010product\u2010information_en.pdf. Accessed April 16 2025."},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.07.005"},{"key":"e_1_2_14_11_1","unstructured":"Eisai Co. Ltd.News Release. Approval of antiepileptic drug FYCOMPA\u00ae in Japan for monotherapy and pediatric indications for partial\u2010onset seizures as well as a new formulation.2025. Available from:https:\/\/www.eisai.com\/news\/2020\/news202004.html. Accessed April 16 2025."},{"key":"e_1_2_14_12_1","unstructured":"Eisai Co. Ltd.Anti\u2010epileptic drug FYCOMPA\u00ae approved in China as monotherapy for partial\u2010onset seizures and pediatric indication for partial\u2010onset seizures.2025. Available from:https:\/\/www.eisai.com\/news\/2021\/news202166.html. Accessed April 16 2025."},{"key":"e_1_2_14_13_1","unstructured":"Eisai News Release.Antiepileptic drug FYCOMPA\u00ae regularly available again in Germany from December following agreement with National Association of Statutory Health Insurance Funds.2025. Available from:https:\/\/www.eisai.com\/news\/news201765.html. Accessed April 16 2025."},{"key":"e_1_2_14_14_1","article-title":"Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross\u2010sectional analysis of recently approved anti\u2010epileptic drugs","volume":"15","author":"Groth A","year":"2017","journal-title":"Ger Med Sci"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.11.012"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12492"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12869"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107691"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.08.015"},{"key":"e_1_2_14_20_1","first-page":"329","article-title":"Cognitive screening tests for patients with epilepsy: a systematic review focusing on test validity and diagnostic accuracy","volume":"18","author":"Kladi A","year":"2021","journal-title":"Hell J Psychol"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00127-3"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006425"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.01.019"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106655"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1120150"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12649"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122797"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.08.001"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00931-4"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106653"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8618-5"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.09.026"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10751-y"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108777"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.12.001"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2022.18.6.653"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.04.015"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202451"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.10.033"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1612"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.06.034"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S343302"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106883"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.121525"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16476"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.010"},{"key":"e_1_2_14_47_1","unstructured":"BecserNA.Monitoring side effects in the daily clinical practice by a brief screening tool EpiTrack. American Epilepsy Society Annual Meeting 2018. Abstract 2.138."},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106856"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:31:31Z","timestamp":1764671491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/epi4.70117"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70117","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"2025-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}